- Home
- GECC vs IFRX Comparison
GECC vs IFRX Comparison
Compare GECC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- IFRX
- Stock Information
- Founded
- GECC 2016
- IFRX 2007
- Country
- GECC United States
- IFRX Germany
- Employees
- GECC N/A
- IFRX N/A
- Industry
- GECC Finance: Consumer Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- IFRX Health Care
- Exchange
- GECC Nasdaq
- IFRX Nasdaq
- Market Cap
- GECC 121.9M
- IFRX 143.7M
- IPO Year
- GECC N/A
- IFRX 2017
- Fundamental
- Price
- GECC $10.87
- IFRX $2.47
- Analyst Decision
- GECC
- IFRX Strong Buy
- Analyst Count
- GECC 0
- IFRX 1
- Target Price
- GECC N/A
- IFRX $8.00
- AVG Volume (30 Days)
- GECC 29.5K
- IFRX 174.5K
- Earning Date
- GECC 02-27-2025
- IFRX 11-08-2024
- Dividend Yield
- GECC 13.42%
- IFRX N/A
- EPS Growth
- GECC N/A
- IFRX N/A
- EPS
- GECC 0.65
- IFRX N/A
- Revenue
- GECC $39,468,000.00
- IFRX $187,930.00
- Revenue This Year
- GECC $17.68
- IFRX $392.79
- Revenue Next Year
- GECC $4.96
- IFRX $156.76
- P/E Ratio
- GECC $16.61
- IFRX N/A
- Revenue Growth
- GECC 16.86
- IFRX 177.12
- 52 Week Low
- GECC $9.55
- IFRX $1.17
- 52 Week High
- GECC $11.31
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- GECC 60.08
- IFRX 53.59
- Support Level
- GECC $10.02
- IFRX $2.16
- Resistance Level
- GECC $10.80
- IFRX $2.65
- Average True Range (ATR)
- GECC 0.34
- IFRX 0.23
- MACD
- GECC 0.03
- IFRX -0.01
- Stochastic Oscillator
- GECC 79.63
- IFRX 52.54
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.